For cIAP-1 mRNA expression, groups of <13 fold and >13 fold were formed, and it was observed that the median survival of breast cancer patients with <13-fold cIAP-1 mRNA expression showed 37.39 months of overall median survival time, while the >13-fold cIAP-1 mRNA expression group had 34.70 months of overall median survival, and the difference among them was found to be significant (p=0.001). Here, BIRC2 is linked to breast carcinoma.